Introduction: Antibodies to the domain 1 of beta 2 glycoprotein I (b 2 GPI-D1) have been suggested as a risk marker for thrombosis in patients with the antiphospholipid syndrome (APS). This cross-sectional study aimed to analyze the clinical utility of a novel chemiluminescence assay for the detection of anti-b 2 GPI-D1 antibodies. Patients and methods: Sera collected from patients with primary or secondary APS (n ¼ 106; 72 with and 34 without history of thrombosis) and controls (n ¼ 272) were tested for anti-b 2 GPI-D1 IgG by chemiluminescence assay (QUANTA Flash) and by two anti-b 2 GPI IgG assays (QUANTA Lite and QUANTA Flash b 2 GPI IgG). Results: Anti-b 2 GPI-D1 IgG titers were significantly higher in patients with thrombosis (P ¼ 0.0032) than those without. At the cut-off of 20 units, which yielded a 99.5% specificity, 24 of 72 (34.9%) patients with thrombosis and four of 34 (11.8%) without thrombosis were anti-b 2 GPI-D1 IgG positive (odds ratio, OR ¼ 4.0). By further optimizing the cut-off specifically for correlation with thrombosis, 20.8% of the patients with thrombosis and 2.9% of the patients without thrombosis were positive (OR ¼ 8.7). The ORs were significantly lower for antibodies to the full-length b 2 GPI by either the chemiluminescence assay or ELISA. Using the anti-b 2 GPI chemiluminescence assay, the OR was 2.3 (recommended cut-off of 20 CU) or 4.1 (optimal cut-off 164.6 CU). Using the anti-b 2 GPI ELISA, the OR was 2.7 (recommended cut-off of 20 units) or 3.7 (optimal cut-off 7.6 units). Conclusion: These data indicate that anti-b 2 GPI-D1 IgG are present more frequently and in higher titers in APS patients with thrombotic complications than in those without.The novel b 2 GPI-D1 chemiluminescence assay appears to be superior to full-length b 2 GPI assays for the risk assessment of thrombotic events in APS patients. Lupus (2016) 25, 911-916.
Introduction
Antiphospholipid syndrome (APS), also known as Hughes syndrome, is an autoimmune disorder characterised by pregnancy loss and/or recurrent thrombosis in arteries and veins. 1 Thrombotic events are mediated by antiphospholipid antibodies (aPL), such as anticardiolipin antibodies (aCL) and/or anti-b2 glycoprotein I (b 2 GPI) and/or the lupus anticoagulant. 1 APS is associated with a wide variety of clinical symptoms, from thrombosis and pregnancy complications to unexplained cutaneous circulatory disturbances (livedo reticularis or pyoderma gangrenosum), thrombocytopenia, hemolytic anemia, and non-bacterial thrombotic endocarditis. 1 APS can occur in isolation or in the presence of other autoimmune disorders, most frequently systemic lupus erythematosus. 1 An international consensus statement on classification criteria for definite APS was published in 1999 2 and revised in 2006. 3 A patient with APS must meet at least one of two clinical criteria (vascular thrombosis or complications of pregnancy) and at least one of three laboratory criteria defined by the presence of aCL, anti-b 2 GPI or the lupus anticoagulant. Although these criteria have been shown to be specific and sensitive for the classification of primary and secondary APS, 4 recent studies have described patients with clinical evidence of APS but who do not fulfil the serological criteria for the disease. 5, 6 b 2 GPI was identified as a primary target of autoantibodies in patients with APS 7 and considerable research has since focused on the functional and clinical significance of these specific autoantibodies. b 2 GPI (also called apolipoprotein H) is a 326 amino acid (aa) protein synthesized by endothelial cells, hepatocytes, and trophoblast cells. 7 The protein consists of five homologous domains of approximately 60 aa each. 8 Domain 5, located at the C terminus, contains a hydrophobic core surrounded by 14 positively charged aa residues that promote electrostatic interactions with plasma membranes via interactions with negatively charged phospholipids. Complexes of b 2 GPI and phospholipid in vivo reveal epitopes that react with natural autoantibodies. 9 The development of recombinant domainspecific b 2 GPI molecules by Iverson et al. in 1998 10 led to a better understanding of the precise significance of autoantibodies to each of the five b 2 GPI domains. Despite wide interest in the potential diagnostic value of these antibodies, the number of studies is limited and their potential clinical utility is being investigated. 11 The objective of this study was to compare the performance and potential utility of a novel chemiluminescence immunoassay (CIA) for the detection of antibodies to domain 1 of anti-b2GPI (b2GPI-D1) and compare it with two commercially available anti-b 2 GPI antibody assays using the full-length antigen.
Patients and methods

Clinically defined samples
Sera from 106 APS patients fulfilling the 2006 revised APS classification criteria 3 were collected at a single clinical center (St Thomas Hospital, King's College, London). Of the 106 APS patients, 72 had a known history of thrombosis (33 venous thrombosis, 25 arterial and 14 both) and the remaining 34 had no history of thrombosis. As controls, 272 samples from healthy individuals and infectious disease patients were used. Ethical approval was obtained from the health research authority (NRES Committee, London) and all patients involved in this study gave their written consent.
Recombinant 2 GPI-D1 antigen
The b 2 GPI-D1 antigen, comprising aas 1-64 of b 2 GPI, 10 was produced in insect cells and purified using common HIS Tag purification protocols. The antigen was found to have a purity of 95% or greater, determined by sodium dodecyl sulphatepolyacrylamide gel electrophoresis and densitometry analysis (data not shown).
Autoantibody assays
The QUANTA Flash b 2 GPI-D1 assay is a novel CIA (Inova Diagnostics, San Diego, USA; CE labelled and 510 k cleared assay) that uses recombinant b 2 GPI-D1 (based on human sequence) coated onto paramagnetic beads and is designed for the BIO-FLASH instrument (Biokit SA, Barcelona, Spain). The principle and protocol of the QUANTA Flash assay system has been previously described. [12] [13] [14] The relative light units (RLUs) are proportional to the amount of isoluminol conjugate that is bound to the human IgG, which in turn is proportional to the amount of anti-b 2 GPI-D1 antibodies bound to the antigen on the beads. Samples above the analytical measuring range were diluted by auto-rerun feature to determine the exact concentration of antib 2 GPI-D1 antibodies. Anti-b 2 GPI antibodies were determined using the QUANTA Lite and the QUANTA Flash b 2 GPI assays (both Inova Diagnostics). Both assays used full-length human native b 2 GPI, obtained as previously described.
Statistical evaluation
Data were statistically evaluated using Analyse-it software (Version 4.0; Analyse-it Software, Ltd., Leeds, UK). Mann-Whitney U and Fisher's exact tests were carried out to analyze the difference between groups. Positive and negative likelihood ratios (LRþ and LR-, respectively) were used to analyze the performance of the assay in identifying APS patients with a history of thrombosis. For all statistic tests, P values less than 0.05 were considered significant. The Spearman equation was used to analyze the agreement between the CIA and ELISA tests. 
Results
At the cut-off that yielded a 99.5% specificity using 272 controls, 24 of 72 (33.3%) patients with thrombosis and three of 34 (8.8%) of those without thrombosis were anti-b 2 GPI-D1 IgG positive. Antibody reactivity to b2GPID1 detected by three methods in patients with and without thrombosis is shown in Figure 1 . The LRþ and LR-were 3.0 and 0.74, respectively. Optimizing the cut-off to yield the highest LRþ and odds ratio (OR) for correlation with thrombosis resulted in 15 of 72 (20.8%) of the patients with thrombosis and one of 34 (2.9%) of the patients without thrombosis being positive for anti-b 2 GPI-D1 antibodies. Using the optimized cut-off, the LRþ and LR-were 7.1 and 0.82, respectively. The ORs were 4.0 for the original and 8.7 for the optimized cut-off. Using the fulllength b 2 GPI CIA, the LRþ was 1.4 (using the recommended cut-off) or 2.8 (using an optimized cutoff of 164.6 CU). Using the b 2 GPI ELISA, the LRþ was 2.2 (recommended cut-off) or 2.4 (optimal cut-off 7.6 units) ( Figure 2 ). ORs were also significantly lower for the full-length molecule Figure 1 Anti-b 2 GPI antibodies in antiphospholipid syndrome (APS) patients with and without thrombosis. The titers of antib 2 GPI antibodies in APS patients with and without thrombosis were compared a.) for the b 2 GPI Domain 1 CIA, b.) for the b 2 GPI CIA and c.) for the b 2 GPI ELISA. Difference between titers reached statistical relevance for b 2 GPI and b 2 GPI D1 CIA, but not for b 2 GPI ELISA. CIA: chemiluminescence immunoassay.
Figure 2
Likelihood and odds ratios for thrombosis as a function of the anti-b 2 GPI antibody titers. With increasing titer of antib 2 GPI Domain 1 the likelihood ratio (LR+) and odds ratio for thrombosis increased significantly and reached about 5 and 9 at a cut-off of 160 CU, respectively. The likelihood of thrombosis was significantly higher for anti-b 2 GPI-D1 antibodies compared to anti-b 2 GPI whole molecule antibodies.
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compared to b 2 GPI-D1. Results are summarized in Table 1 . The quantitative correlation between the b 2 GPI-D1 CIA, b 2 GPI ELISA and b 2 GPI CIA was significant. According to Spearman, the correlation between b 2 GPI-D1 CIA and b 2 GPI ELISA was 0.71 (95% confidence interval (CI) 0.60-0.80), between b 2 GPI CIA and b 2 GPI ELISA 0.78 (95% CI 0.69-0.85) and between b 2 GPI-D1 CIA and b 2 GPI CIA 0.74 (95% CI 0.64-0.82) (Figure 3 ).
Discussion
Anti-b 2 GPI antibodies represent a hallmark in the diagnosis of APS. 1 Consequently, several studies have investigated the epitope distribution of anti-b 2 GPI antibodies. The majority of those antibodies have been reported to bind epitopes located within D1 of b 2 GPI 8,10 comprising different regions of Domain 1. 15 Interestingly, anti-b 2 GPI IgG in sera from asymptomatic patients, individuals with leprosy or children with atopic dermatitis have been reported to recognize epitopes preferentially on Domain 4/5 rather than Domain 1. 16 Although anti-b 2 GPI-D1 antibodies are mainly found in patients with APS, they can also be found in patients with systemic autoimmune rheumatic disease 17 and the ratio between antibodies to D1 versus D4/5 can even be predictive for systemic autoimmunity. 17 Anti-b 2 GPI-D1 antibodies have been detected using several different methods. 15 The majority of studies used a two-step approach using b 2 GPI coated to hydrophobic and hydrophilic microtiter plates. 18 This method is based on the assumption that on hydrophobic plates, only Domain 1 of b 2 GPI is exposed and thus accessible for autoantibody binding. 19 It has been demonstrated that about 50% of anti-b 2 GPI antibodies are directed against D1 using a liquid-phase inhibition assay using whole b 2 GPI immobilized on the solid phase and synthetic b 2 GPI-D1 as inhibitor. 20 In addition, ELISAs based on recombinant b 2 GPI-D1 expressed and purified from insect cells have been developed. 8 Some studies have been performed on research methods to measure antib 2 GPI-D1 antibodies including an international multicenter evaluation, which found a strong association between anti-b 2 GPI-D1 antibodies and a history of thrombosis. 19 Other studies have demonstrated that patients with multiple positive test results (i.e. LA, aCL, and different b 2 GPI isotypes) have a higher risk of developing clinical complications [21] [22] [23] [24] and those patients tend to have a higher prevalence and higher titers of anti-b 2 GPI-D1 antibodies. 20 Until today, QUANTA Flash b 2 GPI-D1 is the only commercial assay for the detection of anti-b 2 GPI-D1 antibodies that has been evaluated.
In our study we found an association between anti-b 2 GPI-D1 antibodies and thrombosis using the novel b 2 GPI-D1 CIA. At high levels, antib 2 GPI-D1 antibodies showed an OR for thrombosis of 9.5. The association with two assays using the full-length b 2 GPI molecule, namely QUANTA Flash b 2 GPI and QUANTA Lite b 2 GPI, showed statistically lower ORs for thrombosis compared to b 2 GPI-D1 CIA, underlining the clinical utility of anti-b 2 GPI-D1 as previously reported. 19, 25, 26 Prospective studies are necessary to confirm the reported clinical associations of anti-b 2 GPI-D1 antibodies, especially the association with thrombosis.
The role of autoantibody titer and multiple autoantibody positivity is increasingly being recognized as important parameters to consider in routine clinical practice. It is not yet clear how anti-b 2 GPI-D1 antibodies, by themselves or in combination with other aPL markers, are most useful in risk assessment and/or diagnosis of APS patients. In addition, scientists are still investigating if fluctuations of anti-b 2 GPI-D1 antibody titers over time and/or variability in anti-b 2 GPI-D1 affinity, as previously reported for anti-b 2 GPI, 27, 28 play an important role in the pathogenesis of anti-b 2 GPI-D1 antibodies. As suggested by Bossuyt 29 for other autoantibodies, and recently by Otomo et al. 21 and Sciascia et al. 30 for high aPL antibodies, the titer of autoantibodies might be an important consideration in the clinical assessment of patients. Further studies are needed to investigate if titer fluctuations have an impact on the risk of developing clinical complications.
In conclusion, we present further evidence that b 2 GPI-D1 represents an important antibody target in APS patients. Its potential diagnostic utility for thrombosis in APS was confirmed by the high positive likelihood ratio seen in this well characterized cohort. Anti-b 2 GP-D1 antibodies measured by CIA might represent a promising method in the risk assessment of thrombosis. Further multicenter studies are needed to confirm their clinical utility.
